ARC as Cancer, Depression and Neurodegenerative Disorder Drug Target

Target Name: ARC

NCBI ID: G23237

Content of Review Report on ARC Target / Biomarker

ARC

ARC as Cancer, Depression and Neurodegenerative Disorder Drug Target

ARC (ARyl-CoA Synthetase) is a enzyme that plays a crucial role in the production of aromatic amino acids, which are the building blocks of many important molecules in the body. Aromatic amino acids are vital for the development and maintenance of tissues, including hair, nails, and bones. They are also important for the production of hormones and neurotransmitters. In addition, ARC is involved in the metabolism of many other molecules, including drugs and toxins.

The drug target (or biomarker) for ARC is currently being studied for its potential role in the treatment of various diseases, including cancer, depression, and neurodegenerative disorders.

One of the main ways that ARC is being targeted for drug development is as a target for cancer. Many cancer treatments are designed to disrupt the supply of aromatic amino acids to cancer cells. By inhibiting the activity of ARC, cancer cells may be forced to stop growing and may be more easily targeted by drugs.

Another potential mechanism by which ARC may be targeted for cancer treatment is by disrupting the production of key signaling molecules in cancer cells. ARC is involved in the production of many signaling molecules that are important for cancer cell growth and survival. By inhibiting the activity of these molecules, ARC may be able to inhibit the growth and survival of cancer cells.

In addition to its potential as a cancer drug target, ARC is also being studied as a potential biomarker for the disease. The ability to detect and measure the activity of ARC is an important step in the development of new treatments for cancer. By measuring the levels of ARC in cancer cells, researchers may be able to determine how effective a particular treatment is. In addition, the ability to detect ARC activity in cancer cells may also be used as a diagnostic tool to determine the presence of the disease.

ARC is also being studied as a potential target for depression. The production of aromatic amino acids is closely linked to the production of serotonin, a neurotransmitter that is involved in mood regulation. In addition, the levels of ARC in the brain are closely tied to the levels of depression. By inhibiting the activity of ARC, researchers may be able to treat depression by increasing the levels of serotonin in the brain.

In addition to its potential as a cancer and depression drug target, ARC is also being studied as a potential target for neurodegenerative disorders. The production of aromatic amino acids is closely linked to the production of many important molecules that are involved in the development and maintenance of neural tissue. In addition, the levels of ARC in the brain are closely tied to the levels of neurodegenerative disorders. By inhibiting the activity of ARC, researchers may be able to treat neurodegenerative disorders by increasing the levels of important molecules in the brain.

In conclusion, ARC is an enzyme that plays a crucial role in the production of aromatic amino acids, which are vital for the development and maintenance of tissues. In addition, ARC is involved in the metabolism of many other molecules, including drugs and toxins. The drug target (or biomarker) for ARC is currently being studied for its potential role in the treatment of cancer, depression, and neurodegenerative disorders. By inhibiting the activity of ARC, researchers hope to develop new treatments for these diseases.

Protein Name: Activity Regulated Cytoskeleton Associated Protein

Functions: Master regulator of synaptic plasticity that self-assembles into virion-like capsids that encapsulate RNAs and mediate intercellular RNA transfer in the nervous system. ARC protein is released from neurons in extracellular vesicles that mediate the transfer of ARC mRNA into new target cells, where ARC mRNA can undergo activity-dependent translation. ARC capsids are endocytosed and are able to transfer ARC mRNA into the cytoplasm of neurons. Acts as a key regulator of synaptic plasticity: required for protein synthesis-dependent forms of long-term potentiation (LTP) and depression (LTD) and for the formation of long-term memory. Regulates synaptic plasticity by promoting endocytosis of AMPA receptors (AMPARs) in response to synaptic activity: this endocytic pathway maintains levels of surface AMPARs in response to chronic changes in neuronal activity through synaptic scaling, thereby contributing to neuronal homeostasis. Acts as a postsynaptic mediator of activity-dependent synapse elimination in the developing cerebellum by mediating elimination of surplus climbing fiber synapses. Accumulates at weaker synapses, probably to prevent their undesired enhancement. This suggests that ARC-containing virion-like capsids may be required to eliminate synaptic material. Required to transduce experience into long-lasting changes in visual cortex plasticity and for long-term memory (By similarity). Involved in postsynaptic trafficking and processing of amyloid-beta A4 (APP) via interaction with PSEN1 (By similarity). In addition to its role in synapses, also involved in the regulation of the immune system: specifically expressed in skin-migratory dendritic cells and regulates fast dendritic cell migration, thereby regulating T-cell activation (By similarity)

The "ARC Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARC comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets